Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Rita Leggett strongly opposed losing the experimental brain implant that helped her manage severe epilepsy. But the available accounts do not establish that doctors operated while she was refusing consent: later legal and ethics analyses say she ultimately agreed to removal. The sharper concern is that NeuroVista’s collapse left her with no practical way to keep using or supporting the device she said had transformed her life.
A seizure-warning device changed what Leggett felt able to do
Leggett, an Australian woman who had lived with severe epilepsy since childhood, received an experimental seizure-monitoring brain-computer interface in 2010, at age 49. Before the trial, the unpredictability of seizures limited ordinary activities and her sense of independence.
The device was not a general-purpose “mind-reading” implant, nor was it designed to cure epilepsy. Electrodes on the brain’s surface monitored electrical activity. Signals went to an external system, where software looked for patterns associated with an impending seizure. A portable alert gave Leggett warning so she could take medication or move to a safer place. Its purpose was to help her respond to risk, not eliminate the underlying condition.
Leggett reported that the warning made her feel safer and more confident, and helped her make plans, see friends and participate more fully in daily life. Those are her experiences, not evidence that the system would work the same way for every person with epilepsy. In accounts of the case, she described feeling closely connected to the device—like she had become “one” with it.
#1 Best Overall
Why was the implant removed?
The system was part of a research trial run by NeuroVista. The company ran out of money and ceased operations. When the trial ended, the ongoing technical support and maintenance needed to keep the experimental system available were no longer feasible. Participants were told their implants had to be removed.
Leggett and her husband tried to find a way to keep hers, including attempting to buy it and remortgaging their home, but they were unsuccessful. She was reportedly the last trial participant to undergo explantation. The accounts describe a corporate and post-trial support failure—not a medical emergency caused by the implant—as the reason she could not continue with it.
Buying a device would not necessarily have solved the problem. An implanted system depends on more than the hardware in a patient’s body: external equipment, software, calibration, troubleshooting and clinical oversight can all matter. The reporting available on Leggett’s case does not establish the complete contractual ownership terms, so it is more accurate to say she could not secure a workable way to retain and use the system than to say the company simply repossessed it.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Rank #2
- Plants vs Zombies paperback book
Does “against her will” mean doctors operated without consent?
Not on the evidence described in the available reporting and later analyses. “Against her will” captures Leggett’s strong opposition to losing the implant and the importance she placed on it. But legal and ethics discussions of the case describe her as ultimately consenting to the removal, albeit reluctantly. The sources do not establish that surgeons physically forced the operation or performed it while she was actively refusing consent.
That distinction matters. Wanting to keep an implant, facing intense pressure to remove it, and undergoing surgery without consent are different situations. Leggett’s case is troubling even without claiming the last one: after the sponsor disappeared and support ended, she had no viable route to continue with a device she wanted to keep. Consent to surgery under those circumstances may be formally given while the available choices are profoundly undesirable. The case therefore raises a question about how meaningful consent is when a trial’s collapse has removed the alternatives.
Nor do the cited analyses establish that the removal was illegal. They examine ethical and legal questions around consent and explantation; they are not evidence of a court ruling that Leggett’s procedure was unlawful.
The loss was about more than hardware
Leggett described the removal as traumatic and said she did not feel as safe or secure afterward. She also said she no longer felt like the same happy, confident person. These are her reported feelings, not a psychiatric diagnosis. They help explain why the loss cannot be understood only as the end of a device trial: for her, the warning system had become tied to confidence, independence and her sense of herself.
That does not mean every implant becomes part of a patient’s identity, or that an unsupported device should always be left in place. An implant can pose medical risks if it fails, becomes infected or cannot be monitored safely. But removal is also an invasive intervention, and losing a capability that conventional care cannot replace may bring serious practical and psychological consequences. Both sides of that decision require attention.
The post-trial problem experimental implants expose
Research trials have an endpoint; a participant’s needs do not necessarily end with the study. Neural devices make that gap especially visible because they may rely on a sponsor for software, replacement components, maintenance, data handling or specialist support. When a company closes, a patient can be left physically dependent on technology for which no one remains responsible.
Leggett’s case is part of a wider ethical discussion about what should happen when investigational implants are no longer supported. Reporting has also compared the issue with patients who received experimental bionic eyes and later lost access when systems became obsolete. Those cases illustrate a shared post-trial challenge, but they do not necessarily have the same medical or legal facts.
For future trials, consent should address not just implantation but the possible end of support. Researchers and sponsors should plan for who will maintain and monitor a device, who pays for that care or for removal, what happens if a company becomes insolvent, whether another organization can take over, and how patients can access psychological support or rehabilitation if device-enabled function is lost. The agreement should also make clear what happens to external equipment and neural data, and whether the patient has any route to continue using the system.
Recommended Free Tools
Consent to implantation should not be treated as automatic consent to later explantation. Guidance on investigational neural-device studies supports obtaining separate, informed consent for removal. At the same time, patient autonomy does not make every continued use safe: if an implant creates a serious medical danger, removal may become medically necessary. A sponsor’s bankruptcy by itself, however, is not the same thing as an urgent medical complication.
Best Value
Questions to ask before joining an implant trial
Anyone considering an investigational implant should ask the study team to explain, in writing and in plain language:
- Who owns or controls the implanted hardware, external equipment, software and recorded data?
- Who will provide clinical monitoring, maintenance and repairs during the trial—and after it ends?
- What happens if the sponsor closes, is acquired or stops supporting the device? Can another organization take over?
- Who pays for long-term care, replacement parts or explantation, and can the participant refuse removal?
- What medical risks could make continued use unsafe, and who will advise the patient if the sponsor is no longer operating?
- What practical support, psychological care or rehabilitation is available if the device stops working or is removed?
These questions do not determine what Leggett should have chosen, or whether keeping her particular system would have been safe. They point to a responsibility that should be addressed before a trial begins: a plan for the participant if the technology works for them but the company behind it does not survive.
The central issue in Leggett’s story is not that a company’s failure automatically entitles a patient to keep an experimental implant indefinitely. It is that a trial can end with a patient facing the loss of a valued capability and surgery, while the infrastructure that made the device usable has vanished. Her experience shows why post-trial care and the terms of removal belong in the ethics of an implant from the start.
Futurism’s account of Leggett’s case; MIT Technology Review’s 2023 report; a review of ethical, legal and sociocultural issues in neural-device removal; and guidance on investigational neural-device studies and post-trial care.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
